Skip to main content

Table 5 Effects of zafirlukast on sputum inflammatory indices in paired samples

From: Tolerance and rebound with zafirlukast in patients with persistent asthma

 

Zafirlukast (n = 9)

Placebo (n = 11)

 

Baseline

12 weeks

Baseline

12 weeks

*TCC × 10 3 /ml

38.8 (0.6–293.8)

22.8 (0.3–93.8)

41.0 (0.5–176)

41.5 (3.8–109.3)

Sputum eosinophils, %

5.8 (0.8–39.2)

4.0 (0.4–54.6)

5.3 (0.2–14.7)

1.7 (0–39.5)

CysLT pg/ml

331 (182–648)

567 (151–1029)

192 (15–763)

412 (49–1332)

PGE 2 pg/ml

942 (572–1951)

1276 (836–2513)

1245 (479–6155)

959.2 (329–3756)

  1. *Data are expressed as median and (range).